I'm done speculating....well, almost :-)  I don't care what the PPS does between now and top-line, I don't believe its in any way predictive of results.  The only thing that might cause me concern is if the Mcap dropped below that Furstein threshold for trial failure, $300 million USD...I know its for cancer drugs, but I think its a good barormeter regardless.

I will look to see if short interest has climbed of course....just to see if this move down might have been influenced by those borrowing and dumping.